التفاصيل البيبلوغرافية
| العنوان: |
Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. |
| المؤلفون: |
Degeling, Koen1,2 (AUTHOR) koen.degeling@unimelb.edu.au, Wong, Hui-Li3,4 (AUTHOR), Koffijberg, Hendrik1 (AUTHOR), Jalali, Azim3 (AUTHOR), Shapiro, Jeremy5 (AUTHOR), Kosmider, Suzanne6 (AUTHOR), Wong, Rachel3,7,8 (AUTHOR), Lee, Belinda3,4,9 (AUTHOR), Burge, Matthew10 (AUTHOR), Tie, Jeanne3,4,6 (AUTHOR), Yip, Desmond11 (AUTHOR), Nott, Louise12 (AUTHOR), Khattak, Adnan13 (AUTHOR), Lim, Stephanie14 (AUTHOR), Caird, Susan15 (AUTHOR), Gibbs, Peter3,6 (AUTHOR), IJzerman, Maarten1,2,4 (AUTHOR) |
| المصدر: |
PharmacoEconomics. Nov2020, Vol. 38 Issue 11, p1263-1275. 13p. |
| مصطلحات موضوعية: |
DISCRETE event simulation, PROGRESSION-free survival, COLORECTAL cancer, METASTASIS, BEVACIZUMAB |
| مستخلص: |
Background: Simulation models utilizing real-world data have potential to optimize treatment sequencing strategies for specific patient subpopulations, including when conducting clinical trials is not feasible. We aimed to develop a simulation model to estimate progression-free survival (PFS) and overall survival for first-line doublet chemotherapy with or without bevacizumab for specific subgroups of metastatic colorectal cancer (mCRC) patients based on registry data.Methods: Data from 867 patients were used to develop two survival models and one logistic regression model that populated a discrete event simulation (DES). Discrimination and calibration were used for internal validation of these models separately and predicted and observed medians and Kaplan-Meier plots were compared for the integrated DES. Bootstrapping was performed to correct for optimism in the internal validation and to generate correlated sets of model parameters for use in a probabilistic analysis to reflect parameter uncertainty.Results: The survival models showed good calibration based on the regression slopes and modified Hosmer-Lemeshow statistics at 1 and 2 years, but not for short-term predictions at 0.5 years. Modified C-statistics indicated acceptable discrimination. The simulation estimated that median first-line PFS (95% confidence interval) of 219 (25%) patients could be improved from 175 days (156-199) to 269 days (246-294) if treatment would be targeted based on the highest expected PFS.Conclusions: Extensive internal validation showed that DES accurately estimated the outcomes of treatment combination strategies for specific subpopulations, with outcomes suggesting treatment could be optimized. Although results based on real-world data are informative, they cannot replace randomized trials. [ABSTRACT FROM AUTHOR] |
|
Copyright of PharmacoEconomics is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |
Full Text Finder